Case study: Optimization of lentiviral vector production from early stages to GMP

In this webinar we will share with the audience VIVEbiotech´s approach for developing lentiviral vectors from very early stages to GMP, considering highly relevant aspects such as scalability, regulatory compliance, and cost-effectiveness. Different manufacturing steps such as transient transfection using the PEIpro® reagent from Polyplus-transfection will be described.  

Attendees will grow their understanding of  

• LVV production requirements for scalability, regulatory compliance, and cost-effectiveness from early stages through to GMP. 
• How an optimized production process can be adapted to several intermediate scales, streamlining various developmental phases. 
• How to integrally manage LVV quality throughout the duration of the development project. 
• Quality being a key feature of suitability for the final product, we will also overview concepts of quality control and quality assurance.

Claire Wartel-Weill PhD

Director of Quality and Compliance, Polyplus-transfection

Claire Wartel has a PhD in Molecular Pharmacology and Pharmacochemistry from the University of Strasbourg (France, 1999). After several post-docs in different prestigious universities, Claire joined Polyplustransfection in 2004 as Cell Biology project leader and participated in the development of our flagship product jetPRIME®. Claire has taken Quality responsibility since 2007, and nowadays manages the department of Quality and Regulatory Affairs.

Natalia Elizalde PhD

Business Development Director, VIVEviotech

Rakel López de Maturana PhD

Qualified Person, VIVEBiotech

Doctor in Pharmacy (2003, University of Leeds). She started off her research activity in Pharmacology, studying the structure and function of G protein-coupled receptors (GPCRs) (Leeds, 1998-2002, MRC Edinburgh, 2002-2004). She has investigated the mechanisms of pathogenicity in neurodegenerative diseases for more than 10 years; first in Alzheimer’s disease (CIMA University of Navarra, 2005-2009) and later in Parkinson’s disease (Inbiomed Foundation and VIVEbioTECH, San Sebastian-Donostia, 2009-2016).

SPEAKERS

Claire Wartel-Weill PhD

Director of Quality and Compliance, Polyplus-transfection

Natalia Elizalde PhD

Business Development Director, VIVEviotech

Rakel López de Maturana PhD

Qualified Person, VIVEBiotech

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 65

Days

Register

Advancing cell therapy: innovations in polymer-based encapsulation and delivery

J Katz, M Delic-Schlumbohm, B Yevgeniy et al.

5 June

in 43

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 36

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 30

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 29

Days

Register